We are evaluating the safety and feasibility of Diamyd® injections in young people at risk for Type 1 diabetes. This study looks at how the treatment affects their immune system and progression of the disease.
We are studying how rimegepant affects migraine-related reactions in lean and obese individuals. The goal is to understand the relationship between body composition and migraine responses.
We are investigating whether reducing the dose of bleomycin in electrochemotherapy can still effectively treat skin cancers. This study aims to see if patients can benefit from less medication while achieving similar tumor response.
We are studying whether high doses of antiretroviral drugs can reduce the hidden HIV-1 reservoir in people living with HIV. This trial will also assess the safety and effects of the treatment on immune markers.
We are comparing two biologic treatments for severe uveitis in Behçet’s disease to see which one may better improve vision and reduce inflammation. This study will also evaluate the safety of both medications.
We are testing a combination of palbociclib and fulvestrant in women with advanced breast cancer who have not responded to prior treatments. The goal is to evaluate its effectiveness and safety for these patients.
We are studying a combination of treatments for patients with BRAF mutated melanoma and brain metastases. The goal is to see if this approach can help control the disease and improve survival.
We are testing a new chemotherapy method to prevent cancer spread in patients who have had surgery for high-risk colorectal cancer. This study will help us understand its effectiveness and impact on patients' quality of life.
We are studying the safety and effectiveness of brigatinib in children and young adults with ALK+ Anaplastic Large Cell Lymphoma and other solid tumors. This trial aims to find the best dose and understand how the drug works in these patients.
We are studying how different diabetes medications affect fat tissue function in people with type 2 diabetes. This research may help us understand which drug works best for improving health outcomes.
We are studying whether statin treatment guided by genetic risk can lower heart disease events in individuals at high risk. The trial will also look at how well patients accept this personalized approach and its effects on their health.
We are studying whether stopping Omalizumab after long-term treatment is as effective as continuing it for patients with well-controlled severe allergic asthma. This trial aims to assess asthma control and quality of life over time.
We are exploring a new treatment combination for patients with metastatic pancreatic cancer to see if it helps improve survival and understand resistance to therapy. This study aims to assess safety and effectiveness while analyzing how the cancer may resist treatment.
We are testing a new immunotherapy using activated NK cells for children, adolescents, and young adults with refractory sarcomas. The goal is to evaluate its safety and effects after chemotherapy or radiotherapy.
We are studying how different cancer treatments affect speech understanding in noise and overall quality of life for patients. This research may help us understand the cognitive effects of these treatments over time.
We are studying a new treatment combining dostarlimab with CAPEOX for people with untreated Stage III colon cancer. The goal is to see if this combination is more effective and safe compared to CAPEOX alone.
We are investigating whether [177Lu]Lu-DOTATATE can effectively treat recurrent meningioma compared to standard care. The study will also look at safety and quality of life for participants.
We are studying whether using specially modified immune cells can help patients tolerate their new kidney better than standard treatments. The trial also looks at the safety of this new approach in preventing infections and other complications.
We are comparing two oral antibiotics to see which one better resolves urinary symptoms in men with acute bacterial prostatitis. The study will also look at any side effects and the effectiveness of the treatments over time.
We are investigating whether stopping disease-modifying therapies is safe for people aged 55 and over with inactive relapsing-remitting multiple sclerosis. The study will help us understand its effects on relapse rates, disability, and quality of life.